MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Gautam Kollu as Chief Commercial Officer.
“We are very pleased to welcome Gautam, who brings extensive experience in accelerating market development efforts to support the adoption of novel technologies in the genomics space,” said Hans Bishop, Chief Executive Officer at GRAIL. “It’s an exciting time for our company, and Gautam’s strategic leadership will be invaluable as we work to advance our multi-cancer early detection test toward commercialization.”
“I’m thrilled to join GRAIL in its bold pursuit to transform cancer care through early detection,” said Mr. Kollu. “I look forward to building a leading commercial organization in support of our first-of-kind multi-cancer early detection test and our mission to decrease the burden of cancer and save lives.”
Mr. Kollu joins GRAIL from Illumina, Inc. where he most recently served as Vice President, Global Market Development and led the teams that drove the commercial adoption of genomics in multiple applications including noninvasive prenatal testing and liquid biopsy. Prior to that, Mr. Kollu was the Vice President of Marketing, Medical Affairs, and Business Development at Natera, Inc. Previously, Mr. Kollu was the Vice President of Commercial at Exelixis, Inc., and also worked at Genentech, Inc. where he held multiple marketing and commercial roles. Mr. Kollu began his career at Procter & Gamble, Inc. He received a B. Tech. from the Indian Institute of Technology at Bombay and an MBA from the Wharton School at the University of Pennsylvania.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is located in Menlo Park, California. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.